About Pangen Biotech
Pangen Biotech is a company founded in 2010.. The company has 75 employees as of December 31, 2024. Pangen Biotech operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Employees 75 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pangen Biotech, Inc.
-
Annual Revenue
$9.95 M (USD)100.58as on Dec 31, 2024
-
Net Profit
$639.82 K (USD)0as on Dec 31, 2024
-
EBITDA
$1.54 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
$10.23 M (USD), Post-IPO
Nov 07, 2024
-
Investors
Huons
& 1 more
-
Employee Count
75
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pangen Biotech
Pangen Biotech is a publicly listed company on the KRX with ticker symbol 222110 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Pangen Biotech
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $10.2M
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Post-IPO - Pangen Biotech | Valuation |
investors |
|
| Nov, 2022 | Amount | Post-IPO - Pangen Biotech | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pangen Biotech
Pangen Biotech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Huons and CrystalGenomics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Limited information is available on core activities of Huons.
|
Founded Year | Domain | Location | |
|
Clinical stage pharmacy company focused on the novel drugs in areas of inflammation, oncology, and infectious disease
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pangen Biotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pangen Biotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pangen Biotech Comparisons
Competitors of Pangen Biotech
Pangen Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| domain | founded_year | HQ Location |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pangen Biotech
Frequently Asked Questions about Pangen Biotech
When was Pangen Biotech founded?
Pangen Biotech was founded in 2010 and raised its 1st funding round 12 years after it was founded.
Who is the current CEO of Pangen Biotech?
Jae Hong Jang is the current CEO of Pangen Biotech.
How many employees does Pangen Biotech have?
As of Dec 31, 2024, the latest employee count at Pangen Biotech is 75.
What is the annual revenue of Pangen Biotech?
Annual revenue of Pangen Biotech is $9.95M as on Dec 31, 2024.
What does Pangen Biotech do?
Pangen Biotech was established in 2010 as a player in the biotechnology sector. Biosimilars and biologics, including EPO, Factor VIII, and G-CSF, are developed by the company. Emphasis is placed on the development and commercialization of these products. Operations involve research and market introduction within the biologics field, with key leadership provided by executives such as Jae Hong Jang and Youngboo Kim.
Who are the top competitors of Pangen Biotech?
Pangen Biotech's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
Is Pangen Biotech publicly traded?
Yes, Pangen Biotech is publicly traded on KRX under the ticker symbol 222110.
Who are Pangen Biotech's investors?
Pangen Biotech has 2 investors. Key investors include Huons, and CrystalGenomics.
What is Pangen Biotech's ticker symbol?
The ticker symbol of Pangen Biotech is 222110 on KRX.